Webcast ImageWebcast
Cidara Therapeutics, Inc. Conference Call (Replay)
02/21/17 at 8:30 a.m. ET
Cidara Therapeutics, Inc. Conference Call
Tuesday, February 21, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
02/21/17Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track Company to Host Conference Call Today at 5:30 a.m. PT SAN DIEGO, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported that the randomized, controlled Phase 2 RADIANT clinical ... 
01/04/17Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
Topline Data Expected in First Quarter 2017 SAN DIEGO--(BUSINESS WIRE)--Jan. 4, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the RADIANT trial, a Phase 2 randomized trial evaluating the safety, tolerability and efficacy of two topical treatment regimens of the novel echinocandin antifungal, CD101, in w...